WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering

WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Drawing on years of experience in the public and private sectors, our lawyers handle a range of litigation involving the federal government, state and foreign governments, and complex regulatory regimes.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the public offering of 8,538,750 shares, reflecting the full exercise of the underwriters’ option to purchase 1,113,750 additional shares, of common stock by Celldex Therapeutics, Inc. The offering priced on November 7, 2023 and closed on November 10, 2023. Celldex received approximately $230.5 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses.

The WilmerHale team representing the underwriters included Lisa Firenze, Scott Lunin, Liz Graffeo, and Giancarlos Rodriguez with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel